Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network
The treatment of medulloblastoma has evolved considerably over the last 10 years. Treatment intensity is now stratified within clinical trials, using risk-associated clinical features and molecular biomarkers, aimed at maximising cure rates whilst minimising long-term disease and therapy-associated...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X24000655 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422478398455808 |
|---|---|
| author | S. Bailey S. Jacobs M. Kourti M. Massimino N. Andre F. Doz C. Dufour S. Vennarini L. Padovani K. Aquilina U. Thomale A. Joshi T. Pietsch S. Avula G. Morana S. Rutkowski B. Pizer SC Clifford |
| author_facet | S. Bailey S. Jacobs M. Kourti M. Massimino N. Andre F. Doz C. Dufour S. Vennarini L. Padovani K. Aquilina U. Thomale A. Joshi T. Pietsch S. Avula G. Morana S. Rutkowski B. Pizer SC Clifford |
| author_sort | S. Bailey |
| collection | DOAJ |
| description | The treatment of medulloblastoma has evolved considerably over the last 10 years. Treatment intensity is now stratified within clinical trials, using risk-associated clinical features and molecular biomarkers, aimed at maximising cure rates whilst minimising long-term disease and therapy-associated side-effects. In Europe, we have developed a long-term strategy of using randomised trials to test stratified treatments across all medulloblastoma disease demographics, and to investigate further stratification using biological analysis of the samples collected. Importantly, care must be taken not to adopt experimental arms from trial protocols into routine practice, prior to trials’ results being available. Moreover, there are time periods when trials are not open to recruitment for all the various risk-groups. These guidelines, developed under the auspices of SIOP-Europe and the European Reference Network for Paediatric Oncology, ERN PaedCan, review recent and current trials, alongside the literature, to provide evidence-based guidance for the contemporary therapy of medulloblastoma. |
| format | Article |
| id | doaj-art-273dabc371e24b97bfa27149cb87b9cf |
| institution | Kabale University |
| issn | 2772-610X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-273dabc371e24b97bfa27149cb87b9cf2025-08-20T03:31:05ZengElsevierEJC Paediatric Oncology2772-610X2025-06-01510020510.1016/j.ejcped.2024.100205Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference NetworkS. Bailey0S. Jacobs1M. Kourti2M. Massimino3N. Andre4F. Doz5C. Dufour6S. Vennarini7L. Padovani8K. Aquilina9U. Thomale10A. Joshi11T. Pietsch12S. Avula13G. Morana14S. Rutkowski15B. Pizer16SC Clifford17Great North Children’s Hospital and Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom; Corresponding author.Department of Pediatric Oncology University Hospitals Leuven, Leuven, Belgium; Department of Oncololgy, Pediatric Oncology, KU Leuven, Leuven, Belgium3rd Department of Pediatrics, Aristotle University of Thessaloniki and Hippokration General Hospital, Thessaloniki, GreeceFondazione IRCCS Istituto Nazionale dei Tumori, Milano, ItalyDepartment of Pediatric Hematology, Immunology and Oncology, APHM, La Timone Children’s Hospital, Marseille, France; Aix Marseille University, Marseille, FranceSIREDO Centre (Care, innovation, research in pediatric, adolescent and young adults oncology), Institut Curie and Unviversity Paris Cité, Paris, FranceGustave Roussy, Department of Child and Adolescent Oncology, Villejuif, FrancePediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, ItalyDepartment of Radiation Oncology, APHM, Aix Marseille University, Marseille, UMR7051, FranceDepartment of Neurosurgery, Great Ormond Street Hospital, London, UKPediatric Neurosurgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, Berlin, GermanyDepartment of Neuropathology, Royal Victoria Infirmary, Newcastle upon Tyne, United KingdomDepartment of Neuropathology & DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn, GermanyDepartment of Radiology, Alder Hey NHS Foundation Trust, Liverpool, United KingdomDepartment of Neurosciences, University of Turin, Turin, ItalyDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyUniversity of Liverpool, United KingdomWolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, United KingdomThe treatment of medulloblastoma has evolved considerably over the last 10 years. Treatment intensity is now stratified within clinical trials, using risk-associated clinical features and molecular biomarkers, aimed at maximising cure rates whilst minimising long-term disease and therapy-associated side-effects. In Europe, we have developed a long-term strategy of using randomised trials to test stratified treatments across all medulloblastoma disease demographics, and to investigate further stratification using biological analysis of the samples collected. Importantly, care must be taken not to adopt experimental arms from trial protocols into routine practice, prior to trials’ results being available. Moreover, there are time periods when trials are not open to recruitment for all the various risk-groups. These guidelines, developed under the auspices of SIOP-Europe and the European Reference Network for Paediatric Oncology, ERN PaedCan, review recent and current trials, alongside the literature, to provide evidence-based guidance for the contemporary therapy of medulloblastoma.http://www.sciencedirect.com/science/article/pii/S2772610X24000655MedulloblastomaSurgeryRadiotherapyChemotherapyRisk-stratified treatment |
| spellingShingle | S. Bailey S. Jacobs M. Kourti M. Massimino N. Andre F. Doz C. Dufour S. Vennarini L. Padovani K. Aquilina U. Thomale A. Joshi T. Pietsch S. Avula G. Morana S. Rutkowski B. Pizer SC Clifford Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network EJC Paediatric Oncology Medulloblastoma Surgery Radiotherapy Chemotherapy Risk-stratified treatment |
| title | Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network |
| title_full | Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network |
| title_fullStr | Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network |
| title_full_unstemmed | Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network |
| title_short | Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network |
| title_sort | medulloblastoma therapy consensus treatment recommendations from siop europe and the european reference network |
| topic | Medulloblastoma Surgery Radiotherapy Chemotherapy Risk-stratified treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X24000655 |
| work_keys_str_mv | AT sbailey medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT sjacobs medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT mkourti medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT mmassimino medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT nandre medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT fdoz medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT cdufour medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT svennarini medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT lpadovani medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT kaquilina medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT uthomale medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT ajoshi medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT tpietsch medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT savula medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT gmorana medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT srutkowski medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT bpizer medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork AT scclifford medulloblastomatherapyconsensustreatmentrecommendationsfromsiopeuropeandtheeuropeanreferencenetwork |